Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (8 quarters reported)
$137M in Q4 2020 → $38.3M now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Ngm Biopharmaceuticals Inc | 44.4% | Unchanged | 1,298,908 | $17M |
| Revolution Medicines Inc | 35.3% | Unchanged | 685,011 | $13.5M |
| Nurix Therapeutics Inc | 11.1% | Unchanged | 327,123 | $4.26M |
| Rapt Therapeutics Inc | 9.1% | Unchanged | 145,401 | $3.5M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.
quarter ended September 30, 2022 · filed November 14, 2022
No position changes this quarter.
quarter ended June 30, 2022 · filed August 12, 2022
No position changes this quarter.
quarter ended March 31, 2022 · filed May 16, 2022
No position changes this quarter.
quarter ended December 31, 2021 · filed February 11, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nurix Therapeutics Inc | Trimmed | −234,451 | −$6.79M | 17.2% |
quarter ended September 30, 2021 · filed November 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CP Constellation Pharmaceuticals Inc. | Exited | −1,574,229 | −$53.2M | — |
| Nurix Therapeutics Inc | Trimmed | −124,700 | −$3.74M | 24.9% |
quarter ended June 30, 2021 · filed August 16, 2021
No position changes this quarter.
quarter ended March 31, 2021 · filed May 17, 2021
No position changes this quarter.
Loading...
